Comparison of patients' characteristics and response to rituximab induction among all patients (n = 108), between those who received maintenance or not (n = 98), and between 1-y or 2-y maintenance (n = 75)
| . | . | No maintenance* . | Maintenance* . | . | Maintenance, 1 y† . | Maintenance, 2 y† . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient characteristics . | All patients, no. (%) . | No. . | % . | No. . | % . | P . | No.† . | % . | No.† . | % . | P . |
| Age, median (range), y | 65 (41-91) | ||||||||||
| Age (≥70 y) | 38/108 (35) | 11/22 | 50 | 24/76 | 32 | .11 | 17/48 | 35 | 7/27 | 26 | .40 |
| Sex (male) | 52/108 (48) | 11/22 | 50 | 36/76 | 47 | .83 | 22/48 | 46 | 13/27 | 48 | .85 |
| B symptoms (yes) | 7/108 (6) | 1/22 | 5 | 5/76 | 7 | .73 | 4/48 | 8 | 1/27 | 4 | .44 |
| LDH (elevated) | 45/106 (43) | 12/22 | 55 | 30/74 | 41 | .25 | 24/47 | 51 | 6/26 | 23 | .02 |
| Hemoglobin (<10 g/dL) | 32/100 (30) | 10/22 | 46 | 21/75 | 28 | .12 | 13/47 | 28 | 8/27 | 30 | .46 |
| Thrombocytopenia (<100 × 109/L) | 18/104 (17) | 6/22 | 27 | 10/75 | 13 | .12 | 3/47 | 6 | 7/27 | 26 | .018 |
| Lymphocytes (≥4 × 109/L) | 45/104 (43) | 7/20 | 35 | 33/75 | 44 | .47 | 20/47 | 43 | 13/27 | 48 | .64 |
| Paraproteinemia | 31/93 (34)‡ | 7/17 | 41 | 23/68 | 34 | .57 | 11/40 | 28 | 12/27 | 44 | .15 |
| Extrahilar lymphadenopathy (yes) | 30/108 (28) | 7/22 | 32 | 18/76 | 24 | .44 | 12/48 | 25 | 5/22 | 19 | .52 |
| PS >0 | 12/108 (11) | 3/22 | 14 | 9/76 | 12 | .82 | 7/48 | 15 | 2/27 | 7 | .36 |
| Spleen size, median (range), cm | 20 (16-25) | ||||||||||
| Spleen size (>20 cm) | 36/105 (34) | 6/20 | 30 | 24/75 | 32 | .86 | 14/47 | 30 | 9/27 | 33 | .75 |
| HPLL/SLSG (group B/C) | 64/104 (62) | 16/22 | 73 | 42/73 | 58 | .20 | 30/46 | 65 | 11/26 | 42 | .059 |
| Response to induction | .48§ | .027§ | |||||||||
| CR | 47/106 (44) | 9/22 | 41 | 38/76 | 50 | NA | 28/48 | 58 | 10/27 | 37 | NA |
| CRu | 22/106 (21) | 7/22 | 32 | 15/76 | 20 | NA | 11/48 | 23 | 4/27 | 15 | NA |
| PR | 29/106 (27) | 6/22 | 27 | 23/76 | 30 | NA | 9/48 | 19 | 13/27 | 48 | NA |
| SD | 7/106 (7) | 0 | 0 | 0 | 0 | NA | 0 | 0 | 0 | 0 | NA |
| PD | 1/106 (1) | 0 | 0 | 0 | 0 | NA | 0 | 0 | 0 | 0 | NA |
| Nonevaluable | 2/108 (—) | 0 | 0 | 0 | 0 | NA | 0 | 0 | 0 | 0 | NA |
| . | . | No maintenance* . | Maintenance* . | . | Maintenance, 1 y† . | Maintenance, 2 y† . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient characteristics . | All patients, no. (%) . | No. . | % . | No. . | % . | P . | No.† . | % . | No.† . | % . | P . |
| Age, median (range), y | 65 (41-91) | ||||||||||
| Age (≥70 y) | 38/108 (35) | 11/22 | 50 | 24/76 | 32 | .11 | 17/48 | 35 | 7/27 | 26 | .40 |
| Sex (male) | 52/108 (48) | 11/22 | 50 | 36/76 | 47 | .83 | 22/48 | 46 | 13/27 | 48 | .85 |
| B symptoms (yes) | 7/108 (6) | 1/22 | 5 | 5/76 | 7 | .73 | 4/48 | 8 | 1/27 | 4 | .44 |
| LDH (elevated) | 45/106 (43) | 12/22 | 55 | 30/74 | 41 | .25 | 24/47 | 51 | 6/26 | 23 | .02 |
| Hemoglobin (<10 g/dL) | 32/100 (30) | 10/22 | 46 | 21/75 | 28 | .12 | 13/47 | 28 | 8/27 | 30 | .46 |
| Thrombocytopenia (<100 × 109/L) | 18/104 (17) | 6/22 | 27 | 10/75 | 13 | .12 | 3/47 | 6 | 7/27 | 26 | .018 |
| Lymphocytes (≥4 × 109/L) | 45/104 (43) | 7/20 | 35 | 33/75 | 44 | .47 | 20/47 | 43 | 13/27 | 48 | .64 |
| Paraproteinemia | 31/93 (34)‡ | 7/17 | 41 | 23/68 | 34 | .57 | 11/40 | 28 | 12/27 | 44 | .15 |
| Extrahilar lymphadenopathy (yes) | 30/108 (28) | 7/22 | 32 | 18/76 | 24 | .44 | 12/48 | 25 | 5/22 | 19 | .52 |
| PS >0 | 12/108 (11) | 3/22 | 14 | 9/76 | 12 | .82 | 7/48 | 15 | 2/27 | 7 | .36 |
| Spleen size, median (range), cm | 20 (16-25) | ||||||||||
| Spleen size (>20 cm) | 36/105 (34) | 6/20 | 30 | 24/75 | 32 | .86 | 14/47 | 30 | 9/27 | 33 | .75 |
| HPLL/SLSG (group B/C) | 64/104 (62) | 16/22 | 73 | 42/73 | 58 | .20 | 30/46 | 65 | 11/26 | 42 | .059 |
| Response to induction | .48§ | .027§ | |||||||||
| CR | 47/106 (44) | 9/22 | 41 | 38/76 | 50 | NA | 28/48 | 58 | 10/27 | 37 | NA |
| CRu | 22/106 (21) | 7/22 | 32 | 15/76 | 20 | NA | 11/48 | 23 | 4/27 | 15 | NA |
| PR | 29/106 (27) | 6/22 | 27 | 23/76 | 30 | NA | 9/48 | 19 | 13/27 | 48 | NA |
| SD | 7/106 (7) | 0 | 0 | 0 | 0 | NA | 0 | 0 | 0 | 0 | NA |
| PD | 1/106 (1) | 0 | 0 | 0 | 0 | NA | 0 | 0 | 0 | 0 | NA |
| Nonevaluable | 2/108 (—) | 0 | 0 | 0 | 0 | NA | 0 | 0 | 0 | 0 | NA |
HPLL, hemoglobin, platelets, lactate dehydrogenase (LDH), lymphadenopathy; NA, not applicable; PS, performance status.
The maintenance vs no maintenance comparison includes responders only (n = 98). Two patients with SD after induction also received maintenance, but they are not included in this comparison.
The comparison between 1- vs 2-y maintenance includes 75/76 patients who received maintenance, excluding 1 patient who has not completed maintenance yet.
Immunoglobulin M 20/93 (22%), immunoglobulin G 10/93 (11%), immunoglobulin A 1/93 (1%).
P value reflects the overall comparison across all categories.